Abstract:Dear Editor, “Cardiac magnetic resonance imaging in children with chronic kidney disease and renal transplantation,” a report by Schaefer et al., deals with the problem of uremic cardiomyopathy in children with stage two chronic kidney disease (CKD) (1). Cardiovascular impairments in patients with CKD may be extremely detrimental, with a considerable percentage of fatal outcomes. Schaefer et al. pioneered the use of cardiac magnetic resonance (CMR) imaging, a volume-independent method of accurately assessing cardiac structure and functions in children with CKD and after kidney transplantation (Tx). CMR analysis confirmed the improvement of left ventricular hemodynamic parameters after Tx. The authors emphasize that 2D echocardiography (2D-ECHO), using geometric assumptions, based on ventricular dimensions, is not precise enough because of intraventricular volume changes resulting from different fluid flow rates during dialysis. Schaefer et al. concluded that CMR could be considered a useful complementary method for cardiac diagnostics in patients with CKD. Our studies in children with CKD, using the body surface potential mapping (BSPM), an unconventional electrocardiographic method, revealed significant disturbances in the heart intraventricular conduction system (2, 3). The heart conduction system was assessed by means of isochrone maps, precisely illustrating the simultaneously activated ventricular myocardium sites and the variable and abnormal distribution of ventricular activation times (VAT). The ventricular activation times were prolonged, showing a pattern, specific for complete left bundle branch block (LBBB), and localized in the chest areas, which are not routinely explored by 12-lead ECG. It should be emphasized that all the studied patients with CKD did not demonstrate conduction abnormalities in standard ECG or left ventricular hypertrophy or compromised cardiac systolic function in echocardiography. The above-mentioned BSPM values were suggestive of seriously impaired left ventricular conduction in the children with CKD, regardless of treatment options. It is also of interest that the LBBB pattern in the isochrone maps after Tx was transformed to incomplete LBBB, indicating improved heart conduction after the kidney transplantation. Our results support Schaeffer et al.’s observations that conventional examination modes, such as ECG or ECHO, do not sufficiently reflect the actual cardiac status in children with CKD, thus encouraging researchers to invest their intellectual resources into designing a new diagnostic apparatus, free of the above-mentioned defects in precision and consistency.

Cis-[Pt(ii) (1R,2r-Dach)(3-acetoxy-1,1-cyclobutanedicarboxylato)], a Water-Soluble, Oxalate-Free and Stable Analogue of Oxaliplatin: Synthesis, Characterization, and Biological Evaluations.

Strategy to Regulate the Stability and Reduction Rate of Oxaliplatin-Based Pt(IV) Complexes: Cocrystallization

Synthesis, Reactivity Studies and Cytotoxicity of Two Iodidoplatinum(II) Complexes. Does Photoactivation Work?

Slow-Release Drug–Drug Cocrystals of Oxaliplatin with Flavonoids: Delaying Hydrolysis and Reducing Toxicity

23‐Oxa‐analogues of OSW‐1: Efficient Synthesis and Extremely Potent Antitumor Activity

Developing a Highly Stable PLGA-mPEG Nanoparticle Loaded with Cisplatin for Chemotherapy of Ovarian Cancer.

Ligand substitution reactions afford oxaliplatin-based platinum( iv ) complexes bearing axial alkoxido ligands

Pt( iv ) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Supramolecular Chemotherapy: Carboxylated Pillar[6]arene for Decreasing Cytotoxicity of Oxaliplatin to Normal Cells and Improving Its Anticancer Bioactivity Against Colorectal Cancer

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Synthesis, Characterization, and Cytotoxicity Evaluation of Novel Water‐Soluble Cationic Platinum(II) Organometallic Complexes with Phenanthroline and Imidazolic Ligands

Synthesis and Antitumor Activity of (3-Hydroxyacrylato-o,o′) Diammineplatinum(II)

Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl)cyclobutane-1,1-Dicarboxylate as a leaving ligand

Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity

Assessment of cardiac status in children with chronic kidney disease

Structural Studies of Dicycloplatin-an Antitumor Supramolecule

Oxaliplatin Binding to Human Copper Chaperone Atox1 and Protein Dimerization

SBA‐15 Particles as Carriers for a series of Platinum(IV) Complexes with Oxaliplatin Scaffolds Bearing Different Anti‐Inflammatory Drugs: Promising Strategy Against Breast Cancer

Structural study on the interactions of oxaliplatin and linear DNA.

Abstract A172: Dicycloplatin in cancer